Holly A. Swartz, MD | Psychiatrist.com

What Is Meant by the Term “Deprescribing,” and Does It Belong in Our Lexicon?

ASCP Corner

What Is Meant by the Term “Deprescribing,” and Does It Belong in Our Lexicon?

June 2, 2025

The authors encourage the field to destigmatize the term “deprescribing” from its misappropriated usage, explicate its accurate definition, and reclaim its purposeful meaning.

Joseph F. Goldberg, Holly A. Swartz, Rajnish Mago, et al

Addressing Unmet Needs in Bipolar Disorder

Academic Highlights

Addressing Unmet Needs in Bipolar Disorder

November 16, 2022

Bipolar disorder presents on a spectrum, with bipolar depression on one end and bipolar I on the other and a host of other presentations in between. As guidelines are...

Joseph F. Goldberg, Holly A. Swartz, Melissa P. DelBello

Original Research

Psychotherapy for Bipolar II Depression

July 11, 2017

Quetiapine has the greatest evidence of efficacy for bipolar II depression, but it is also associated with metabolic side effects. This study compared psychotherapy plus placebo or plus pharmacotherapy....

Michael E. Thase, Holly A. Swartz, Ellen Frank, et al

ASCP Corner

Cardiovascular Disease and Bipolar Disorder: Risk and Clinical Implications

December 15, 2012

Andrea Fagiolini, Holly A. Swartz

Original Research

Pharmacotherapy for the Treatment of Acute Bipolar II Depression: Current Evidence

August 10, 2010

Michael E. Thase, Holly A. Swartz

Article

The Use of Antidepressants in Bipolar Disorder

August 31, 2008

Virginio Salvi, Andrea Fagiolini, Holly A. Swartz, et al

Educational Activity

The Role of Psychosocial Interventions in Bipolar II Disorder: What Do We Know?

May 11, 2008

Holly A. Swartz

Original Research

Prevalence of Obesity and Weight Change During Treatment in Patients With Bipolar I Disorder

June 18, 2002

Patricia R. Houck, David J. Kupfer, Andrea Fagiolini, et al